Skip to main content
 Intended for US residents only

How Should I Take PEMAZYRE?

Be sure to take PEMAZYRE exactly as instructed by your healthcare provider (HCP).

For cholangiocarcinoma, PEMAZYRE is taken on a 21-day cycle; you take one tablet a day for 14 days, followed by a 7-day period where you don’t take any tablets.

Graphic of a chart showing the 21-day cycle of how to take PEMAZYRE
 

Take PEMAZYRE

 

Do not take PEMAZYRE

  • Take PEMAZYRE once a day, at the same time each day
  • PEMAZYRE may be taken with or without food
  • Swallow tablets whole. Do not crush, chew, split, or dissolve
    PEMAZYRE tablets
  • You should not eat or drink grapefruit products during treatment with PEMAZYRE

Your healthcare provider may change your dose of PEMAZYRE, or may temporarily or completely stop treatment if you get certain side effects.

 

Take PEMAZYRE

 

Do not take PEMAZYRE

Treatment Tracker

Graphic of one pill

Download Your Treatment Tracker

to help you keep track of which days you need to take a PEMAZYRE tablet, and which days you do not.

Graphic of two pills

What should I do if I miss a dose of PEMAZYRE?

Talking With Your Healthcare Team

It’s important to tell your healthcare team about any side effects you may experience, even if you are not sure they are related to your treatment.

Your HCP may be able to offer ways to help manage side effects while you are taking PEMAZYRE.

It’s important to frequently talk to your healthcare team about how you are feeling, and how your cholangiocarcinoma and treatment are affecting you. Be sure to tell your healthcare team about any new or worsening symptoms you may have, even if you are not sure if they are related to your disease or its treatment.

Watch Dr Milind Javle, a gastrointestinal oncologist, discuss treatment with PEMAZYRE, including how to take it, what to expect during treatment, and where you can find support.

This video is intended for informational use only, and is not designed to replace the medical advice of your HCP.

Graphic of two pills

HELP KEEP TRACK OF SIDE EFFECTS

Download this Side Effect Discussion Guide

to help keep track of potential side effects to discuss with your healthcare team. They may be able to help manage side effects while you are taking PEMAZYRE.

IncyteCARES for PEMAZYRE

At IncyteCARES for PEMAZYRE, our team can help you understand your insurance coverage, explore financial assistance options, and offer ongoing support.

Learn More 

INDICATIONS AND USAGE

PEMAZYRE is a prescription medicine that is used to treat adults with bile duct cancer (cholangiocarcinoma) that has spread or cannot be removed by surgery:

  • who have already received a previous treatment, and
  • whose tumor has a certain type of abnormal FGFR2 gene

Your healthcare provider will test your cancer for a certain type of abnormal FGFR2 gene and make sure that PEMAZYRE is right for you.

It is not known if PEMAZYRE is safe and effective in children.

PEMAZYRE is approved based on tumor response and duration of response. There are ongoing studies to show whether PEMAZYRE can improve survival or symptoms.

IMPORTANT SAFETY INFORMATION

Before you take PEMAZYRE (pemigatinib), tell your healthcare provider about all of your medical conditions, including if you:

  • have vision or eye problems
  • have kidney problems
  • have liver problems
  • are pregnant or plan to become pregnant. PEMAZYRE can harm your unborn baby or cause loss of your pregnancy (miscarriage). You should not become pregnant during treatment with PEMAZYRE.

Females who can become pregnant:

  • Your healthcare provider should do a pregnancy test before you start treatment with PEMAZYRE.
  • You should use an effective method of birth control during treatment and for 1 week after your last dose of PEMAZYRE. Talk to your healthcare provider about birth control methods that may be right for you.
  • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.

Males with female partners who can become pregnant:

  • You should use effective birth control when sexually active during treatment with PEMAZYRE and for 1 week after your last dose of PEMAZYRE.

 

  • are breastfeeding or plan to breastfeed. It is not known if PEMAZYRE passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of PEMAZYRE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of PEMAZYRE?

PEMAZYRE may cause serious side effects, including:

  • Eye problems. Certain eye problems are common with PEMAZYRE but can also be serious. Eye problems include dry eye or inflamed eyes, inflamed cornea (front part of the eye), increased tears, and a disorder of the retina (an internal part of the eye). You will need to see an eye specialist for a complete eye exam before you begin treatment with PEMAZYRE, every 2 months for the first 6 months, and then every 3 months during treatment with PEMAZYRE.
  • You should use artificial tears or substitutes, hydrating or lubricating eye gels as needed, to help prevent or treat dry eyes.
  • Tell your healthcare provider right away if you develop any changes in your vision during treatment with PEMAZYRE, including: blurred vision, flashes of light, or see black spots. You may need to see an eye specialist right away.
  • High phosphate levels in your blood (hyperphosphatemia) and buildup of minerals in different tissues in your body.
    Hyperphosphatemia is common with PEMAZYRE but can also be serious. High levels of phosphate in your blood may lead to buildup of minerals such as calcium, in different tissues in your body. Your healthcare provider will check your blood phosphate levels during treatment with PEMAZYRE.
  • Your healthcare provider may prescribe changes in your diet or phosphate lowering therapy, or change, interrupt or stop PEMAZYRE if needed.
  • Tell your healthcare provider right away if you develop any muscle cramps, or numbness or tingling around your mouth.

The most common side effects of PEMAZYRE for cholangiocarcinoma include:

  • hair loss
  • diarrhea
  • nails separate from the bed or poor formation of the nail
  • feeling tired
  • change in sense of taste
  • nausea
  • constipation
  • mouth sores
  • dry eyes
  • dry mouth
  • decrease in appetite
  • vomiting
  • joint pain
  • stomach-area (abdominal) pain
  • low phosphate in blood
  • back pain
  • dry skin
  • hair loss
  • diarrhea
  • nails separate from the bed or poor formation of the nail
  • feeling tired
  • change in sense of taste
  • nausea
  • constipation
  • mouth sores
  • dry eyes
  • dry mouth
  • decrease in appetite
  • vomiting
  • joint pain
  • stomach-area (abdominal) pain
  • low phosphate in blood
  • back pain
  • dry skin

These are not all the possible side effects of PEMAZYRE. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects.

You may report side effects to FDA at
1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Keep PEMAZYRE and all medicines out of the reach of children.

General information about the safe and effective use of PEMAZYRE.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PEMAZYRE for a condition for which it is not prescribed. Do not give PEMAZYRE to other people, even if they have the same symptoms you have. It may harm them. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.

Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with PEMAZYRE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.